Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Direct-acting antivirals do not raise HCC risk in hepatitis C patients

22 Jul 2018
Authorities in Malaysia have approved a compulsory license for Hepatitis C treatment, which allows for cheaper generic medication to be produced without the drug patent holder’s consent.

In patients with advanced hepatitis C infections, taking direct-acting antivirals (DAAs) does not increase the risk of subsequent hepatocellular carcinoma (HCC), a recent study has shown.

Researchers conducted a prospective study of 3,917 patients with hepatitis C infection who were taking DAAs (mean age 58.1±11.9 years; 62.2 percent male); only those with fibrosis stage F3 were eligible for inclusion. Cox regression analyses were performed to identify risk factors for HCC development.

Over a mean follow-up of 536.2±197.6 days, 55 new cases of HCC were reported, yielding an overall incidence rate of 0.97 percent patients per year. The corresponding incidence rate in cirrhotic patients was 1.18 percent patients per year.

Multivariate analysis of baseline variables showed that coinfection with hepatitis B virus (hazard ratio [HR], 3.99; 95 percent CI, 1.24–12.91; p=0.021) and APRI (aspartate aminotransferase-to-platelet ratio) score >2.5 (HR, 2.03; 1.14–3.61; p=0.016) were significant and independent risk factors for HCC development.

In 55 patients who developed HCC (mean age 59.15±9.7 years; 37 males), all hepatitis C virus genotypes were present. The time from DAA initiation to HCC diagnosis ranged from 4–57 weeks and averaged 31.8±20.1 weeks. Twenty-two patients developed HCC while on DAA medication.

In relation to virological outcomes, those who experienced sustained virological response (SVR) were less likely to contract the aggressive form of HCC than in those without SVR (54.6 percent vs 12.1 percent). Moreover, the aggressive HCC pattern was more common during the early periods of observation, while the less aggressive form predominated during later follow-ups.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.